According to a fund comparison with the S&P 500 that PFE performed, spinoffs may be just as unlikely to create value as they are likely to create value “The key point I was trying to make on the earnings call … Continued
JNJ’s 24 billion dollar brands–and its diverse portfolio in general–gives it insight and connections with large customers that are increasingly consolidating. “You take we’ve got 24 brands that are billion dollar platforms at Johnson & Johnson, the first and best … Continued
CEO Ian Read prefers a more transparent market system over a one-payer system “So I prefer not a one-payer system, but a graded system where you individually have enough transparency and understand your healthcare policy. So that you can make … Continued
Product pipeline remains strong in all business segments “Across all four of our groups, CVG, MITG, RTG and Diabetes, our new product pipeline is robust and we’re confident we can drive sustainable growth of our new therapies growth vector within … Continued
I came across this chart in a company presentation that I was watching today, which I thought was worth re-posting. It shows that despite a large increase in Pharmaceutical R&D spend over the last 15 years the number of new … Continued
Just for fun, below is an analysis of how much an average hypothetical person would spend on health insurance over the course of his/her lifetime. The analysis is based on the average rate for health insurance for a single covered … Continued